Biologics News
VORANIGO (vorasidenib), FDA Approved for the Treatment of Patients with IDH-mutant Diffuse Glioma, Available at Biologics by McKesson
CARY, N.C., September 25, 2024—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease, was selected by
ZOKINVY (lonafarnib), the only FDA Approved Treatment for Hutchinson-Gilford Progeria Syndrome, Now Exclusively Available at Biologics by McKesson
CARY, N.C., September 10, 2024 –Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease, was selected
RYTELO (imetelstat), FDA Approved for Treatment of Patients with Low- to Intermediate-1 Risk Myelodysplastic Syndromes (MDS) with Transfusion-dependent Anemia, Available at Biologics by McKesson
CARY, N.C., September 9, 2024—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected
CAMCEVI® (leuprolide) 42mg injection emulsion, FDA Approved for Treatment of Advanced Prostate Cancer, Available Exclusively at Biologics by McKesson
CARY, N.C., June 19, 2024—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been
OJEMDA (tovorafenib), FDA Approved for Pediatric Low-Grade Glioma, Available at Biologics by McKesson
CARY, N.C., April 23, 2024 — Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease, was
FABHALTA (iptacopan), FDA Approved for the Treatment of Adults with Paroxysmal Nocturnal Hemoglobinuria, Available at Biologics by McKesson
CARY, N.C., Dec. 20, 2023 — Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was